Drugs / Human Neural Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03282760 | Sep 2017 → May 2021 | secondary progressive multiple sclerosis | Casa Sollievo della Sofferenza IRCCS | Completed | No outcome recorded |
| Phase 1 | NCT01640067 | Dec 2011 → Dec 2015 | amyotrophic lateral sclerosis | Azienda Ospedaliera Santa Maria, Terni, Italy | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Neural Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01640067 ↗ |
| Known as | hNSCs | “We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and...” PMID 25889343 ↗ Jan 20151“Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions).” NCT03282760 ↗ |
| Modality | Cell therapy | “We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials” PMID 25889343 ↗ Jan 2015 |